EK
Dyno Therapeutics uses AI and machine learning to engineer novel adeno-associated virus (AAV) capsids for gene therapy delivery. Its CapsidMap platform applies deep learning to design synthetic AAV vectors with superior tissue targeting and safety profiles, enabling partners to develop gene therapies for muscle, neurological, liver, and ocular diseases.
Dyno Therapeutics uses AI and machine learning to engineer novel adeno-associated virus (AAV) capsids for gene therapy delivery. Its CapsidMap platform applies deep learning to design synthetic AAV vectors with superior tissue targeting and safety profiles, enabling partners to develop gene therapies for muscle, neurological, liver, and ocular diseases.
Founded in 2018 by Eric Kelsic, Sam Sinai, and George Church, Dyno Therapeutics spun out of the Wyss Institute at Harvard University. The founding team had developed a machine-learning approach to engineer AAV capsids in George Church's lab. After operating in stealth, the company publicly launched in May 2020 with over $2 billion in partnership deals with Novartis and Sarepta Therapeutics.
Dyno Therapeutics announced the expansion of its Frontiers Network — adding manufacturing partner Trisk Bio — alongside hosting the second annual Genetic Agency Technology Conference (GATC) in 2026.
At the 2026 J.P. Morgan Healthcare Conference, Dyno Therapeutics unveiled Dyno-yp2, an AI-engineered AAV capsid designed to cross the blood-brain barrier via the transferrin receptor (TfR) pathway, expanding its off-the-shelf capsid lineup for brain gene therapy.
Dyno Therapeutics launched the Dyno Frontiers Program in May 2025, offering therapeutic developers access to Dyno's AI-designed AAV capsid technology including next-generation off-the-shelf capsids.
Roche expanded its collaboration with Dyno Therapeutics, paying $50 million upfront in a deal potentially worth more than $1 billion, to design novel AAV vectors for neurological diseases including brain delivery.
Astellas Pharma and Dyno Therapeutics announced an option and license agreement in December 2021 worth up to $1.6 billion for developing next-generation AAV gene therapy vectors for skeletal and cardiac muscle diseases.
Dyno Therapeutics raised $100 million in Series A financing led by Andreessen Horowitz, with participation from Casdin Capital, GV, Obvious Ventures, and Lux Capital, to accelerate its AI-powered gene therapy capsid platform.
Dyno Therapeutics announced research published in the journal Science demonstrating an artificial intelligence approach to create new AAV capsids for gene therapies, validating the CapsidMap platform technology.
At launch, Dyno Therapeutics announced partnerships with Novartis (eye disease gene therapies) and Sarepta Therapeutics (muscle gene therapies) collectively worth up to $2 billion, marking the company's public debut.
Roche entered a collaboration with Dyno Therapeutics worth up to $1.8 billion in milestone payments to develop novel AAV vectors for neurological and liver gene therapies using Dyno's CapsidMap platform.
Dyno Therapeutics publicly launched in May 2020 with over $2 billion in potential collaboration revenue, announcing deals with Novartis (eye diseases) and Sarepta Therapeutics (muscle diseases) using its CapsidMap AI platform.
Co-Founder & Head of Computation
Harvard University
Sam Sinai is a co-founder of Dyno Therapeutics and was the team's computational expert, contributing deep learning expertise to the CapsidMap platform for engineering novel AAV capsids.
Co-Founder
Harvard University
George Church is a professor at Harvard Medical School and co-founder of Dyno Therapeutics. His lab at the Wyss Institute developed the foundational machine-learning technology for AAV capsid engineering that underpins Dyno's platform.
$109M raised total